Bloodstream infections due to extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for mortality and treatment outcome, with special emphasis on antimicrobial therapy.

Bloodstream infections due to extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for mortality and treatment outcome, with special emphasis on antimicrobial therapy.

Item

http://www.wikidata.org/entity/Q37624439

Q37624439

about

Extended-spectrum beta-lactamases: a clinical update Canadian practice guidelines for surgical intra-abdominal infections Combating antimicrobial resistance: policy recommendations to save lives Nosocomial bloodstream infections caused by Klebsiella pneumoniae: impact of extended-spectrum beta-lactamase (ESBL) production on clinical outcome in a hospital with high ESBL prevalence Carbapenems versus alternative antibiotics for the treatment of bacteraemia due to Enterobacteriaceae producing extended-spectrum β-lactamases: a systematic review and meta-analysis Beyond Susceptible and Resistant, Part II: Treatment of Infections Due to Gram-Negative Organisms Producing Extended-Spectrum β-Lactamases Empiric Piperacillin-Tazobactam versus Carbapenems in the Treatment of Bacteraemia Due to Extended-Spectrum Beta-Lactamase-Producing Enterobacteriaceae Escherichia coli O25b-ST131: a pandemic, multiresistant, community-associated strain.Can a routine follow-up blood culture be justified in Klebsiella pneumoniae bacteremia? A retrospective case-control study Impact of empiric antimicrobial therapy on outcomes in patients with Escherichia coli and Klebsiella pneumoniae bacteremia: a cohort study.Antimicrobial resistance patterns, clinical features, and risk factors for septic shock and death of nosocomial E coli bacteremia in adult patients with hematological disease: A monocenter retrospective study in China.Increasing prevalence of ESBL production among Irish clinical Enterobacteriaceae from 2004 to 2008: an observational study.Bloodstream infections caused by extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae: risk factors, molecular epidemiology, and clinical outcome Recent changes in bacteremia in patients with cancer: a systematic review of epidemiology and antibiotic resistance.Effect of ceftriaxone on the outcome of murine pyelonephritis caused by extended-spectrum-β-lactamase-producing Escherichia coli.Clinical correlation of the CLSI susceptibility breakpoint for piperacillin- tazobactam against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella species Geographical variability in the likelihood of bloodstream infections due to gram-negative bacteria: correlation with proximity to the equator and health care expenditure.Expert systems in clinical microbiology.Impact of inactive empiric antimicrobial therapy on inpatient mortality and length of stay.ESBLs: A Clear and Present Danger?Clinical usefulness of the 2010 clinical and laboratory standards institute revised breakpoints for cephalosporin use in the treatment of bacteremia caused by Escherichia coli or Klebsiella spp.The inoculum effect of antibiotics against CTX-M-extended-spectrum β-lactamase-producing Escherichia coli.Susceptibility of extended-spectrum-beta-lactamase-producing Enterobacteriaceae according to the new CLSI breakpoints.Diagnosis and treatment of extended-spectrum and AmpC beta-lactamase-producing organisms.Carbapenem therapy is associated with improved survival compared with piperacillin-tazobactam for patients with extended-spectrum β-lactamase bacteremia Leukocyte presence does not increase microbicidal activity of Platelet-rich Plasma in vitro.Trends in Expanded-Spectrum Cephalosporin-Resistant Escherichia coli and Klebsiella pneumoniae among Dutch Clinical Isolates, from 2008 to 2012 Predictors of mortality in patients with bloodstream infections caused by extended-spectrum-beta-lactamase-producing Enterobacteriaceae: importance of inadequate initial antimicrobial treatment.Setting and revising antibacterial susceptibility breakpoints.Gut Microbiota-Induced Immunoglobulin G Controls Systemic Infection by Symbiotic Bacteria and Pathogens Carbapenem therapy for bacteremia due to extended-spectrum-β-lactamase-producing Escherichia coli or Klebsiella pneumoniae: implications of ertapenem susceptibility.Clinical characteristics and antimicrobial susceptibility of Bacillus cereus blood stream infections.Klebsiella pneumoniae bloodstream infection: epidemiology and impact of inappropriate empirical therapy.Carriage of Class 1 and 2 Integrons in Quinolone, Extended-Spectrum-β-Lactamase-Producing and Multi Drug Resistant E.coli and K.pneumoniae: High Burden of Antibiotic Resistance.Impact of appropriate empirical antibiotic treatment on recurrence and mortality in patients with bacteraemia: a population-based cohort study.The search for new antimicrobials: why we need new options.Bad bugs need drugs: an update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America.Intra-abdominal infections: considerations for the use of the carbapenems.A systematic review of the methods used to assess the association between appropriate antibiotic therapy and mortality in bacteremic patients.Bloodstream infections caused by extended-spectrum-beta-lactamase- producing Escherichia coli: risk factors for inadequate initial antimicrobial therapy

P2860

Q24534999-747A53A7-8C83-4A2B-A349-7F10A02667F3 Q24599288-CD6A0595-8C7D-4819-8BC2-E188ACB9AF75 Q24632857-401D341E-9DE9-4CB0-939E-2A6FBB7FF50E Q25257162-EC3463F3-F35A-42CF-A33F-047B1404F396 Q27002495-B5CE7E52-CB43-49AE-A632-427997CD791A Q28249617-02AF6F1A-D32B-4AE3-9A51-11DDD4ADC035 Q28551534-25EB542B-E2E2-4E78-AB0F-D3C0B4842C3E Q30396308-B50473DB-0EFC-443F-A87E-A9DC871B6864 Q31125767-43B32861-D4A5-47AF-9E86-72697E8D5D73 Q33369556-BF80EC43-2A58-4BA6-93F9-124F6E05A457 Q33760545-87AD858C-0282-4FB0-B166-3D7F2D3BDFDA Q34269727-D91DE665-EEAE-46F8-93E4-4746F2FB9506 Q34351978-F339A4B3-7396-4F03-A5D9-6DAAECAE12CD Q34564797-A9392DC9-7C4B-45E7-B46E-0922532BADAA Q34597721-97EBB4CF-B316-4C3F-861B-E4BD67F40B61 Q34680546-423C3F61-4D58-4832-BD8A-E6B7842BA357 Q34733530-8A817805-8FD1-45D8-B97B-D88E4A31A5DA Q35090146-D044DACB-45B8-4E2D-8EC9-3D0922E5E921 Q35091494-F791D55D-7558-48E0-819A-5CEBA37ABDFD Q35101453-586EE4A2-F10C-4668-85F1-F6B80CD32611 Q35156063-3AB8F946-7755-4DFB-8877-02FD93B6C23F Q35158603-1A782A93-48D6-4FAE-AFEA-09C5CC52898C Q35192249-841C4F26-06E0-4BA3-8F90-09CC78D79BF5 Q35356144-F4F6EEB2-C469-4C93-99FB-96516408F6C2 Q35715650-FBFCDB7A-7CF9-48D7-AD00-E5E516E65041 Q35724455-C5DBD50E-B00B-4A84-8772-19D0CD6AD4FA Q35779627-87D2DFC4-9A2A-49D0-AE7B-75DC0B14A630 Q35840852-E75D8F50-D72B-4A81-AFEC-8976DDF50E98 Q35913176-C201FEDF-36B3-4A94-8E4B-6E853EB461B2 Q35946361-A25585C6-4D7E-4EB8-8FCA-F5B02A06B4FA Q36018566-9846ADAA-FC58-4B87-9F3C-0F80F9F0B394 Q36061321-D54DE9E9-65AF-4FFB-8146-58D7B99876DF Q36150730-674E9B60-17E5-4AA4-8E40-A804B5F09465 Q36196021-962733D3-A341-4FA5-B7E8-5C7DAA176111 Q36271987-8A915691-85B0-43D0-AA32-C4CCA3BAE08B Q36322113-73F6C99F-8D6C-4410-9F3D-64AC3A37A90C Q36382134-49D39B0D-6DBE-4BDA-B7CD-93B576530044 Q36719679-72F21B4D-23A7-4A1E-B21D-03B4CE302C30 Q36864125-5A92A4E0-71CB-41C6-BD88-8DB73A4F2A55 Q36870786-FFDB3527-1612-4DE3-8394-2ABD1C9C3E0D

P2860

Bloodstream infections due to extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for mortality and treatment outcome, with special emphasis on antimicrobial therapy.

Item

http://www.wikidata.org/entity/Q37624439

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on December 2004

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs